Dianthus Therapeutics, Inc. (DNTH)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Biotechnology (Startups)	2.04M	6.24M	2.83M	6.42M	1.48M
Biotechnology (Startups) Growth	-67.35%	120.63%	-55.96%	334.76%	-
Total	2.04M	6.24M	2.83M	6.42M	1.48M
Total Growth	-67.35%	120.63%	-55.96%	334.76%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
United States	2.04M	6.24M	2.83M	6.42M	1.48M
United States Growth	-67.35%	120.63%	-55.96%	334.76%	-
Total	2.04M	6.24M	2.83M	6.42M	1.48M
Total Growth	-67.35%	120.63%	-55.96%	334.76%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 9, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 3, 2026

Data Sources Report a data error